Valuation: Evaxion A/S

Market Cap 23.27M 20.22M 18.88M 17.33M 32.68M 2.22B 33.25M 223M 87.19M 1.11B 87.4M 85.47M 3.65B P/E 2026 *
-69.8x
P/E 2027 * 69.8x
Enterprise Value 23.27M 20.22M 18.88M 17.33M 32.68M 2.22B 33.25M 223M 87.19M 1.11B 87.4M 85.47M 3.65B EV / Sales 2026 *
-
EV / Sales 2027 * 1.37x
Free-Float
76.93%
Yield 2026 *
-
Yield 2027 * -
1 day-1.06%
1 week-3.46%
Current month-1.06%
1 month-18.18%
3 months-37.93%
6 months-12.54%
Current year-41.51%
1 week 2.77
Extreme 2.77
2.89
1 month 2.77
Extreme 2.77
3.6
Current year 2.77
Extreme 2.77
5.48
1 year 2.52
Extreme 2.52
12.15
3 years 1.2
Extreme 1.2
68.05
5 years 1.2
Extreme 1.2
1,252
10 years 1.2
Extreme 1.2
1,252
Manager TitleAgeSince
Chief Executive Officer 59 2025-11-23
Corporate Officer/Principal 49 2008-08-10
Director of Finance/CFO 53 2024-10-31
Director TitleAgeSince
Chairman 58 2020-11-24
Director/Board Member 56 2017-12-31
Director/Board Member 68 2021-05-24
Date Insider Type Main position Quantity % Market Cap.
3/18/26 Other

Chairman

6,473,997 1.5525%
3/18/26 Other

Director

1,171,030 0.2808%
3/18/26 Other

Chief Financial Officer

968,600 0.2323%
Change 5-day change 1-year change 3-year change Capi.($)
-1.06%-3.46%+6.90%-95.46% 23.27M
-0.36%+0.14%-2.06%+14.33% 48.22B
-2.71%-2.99%+398.09%+472.12% 38.79B
-0.71%+9.45%+27.90%+7.89% 38.41B
-0.71%-3.72%+4.94%+52.45% 34.88B
-2.41%+1.96%+11.68%+38.17% 29.19B
-0.66%-2.73%+35.50%+122.17% 16B
-0.19%-3.93% - - 16.05B
-0.62%+1.23%+2.76%+15.05% 13.53B
-3.15%-6.14%-4.82%-36.90% 12.22B
Average -1.26%-0.94%+53.43%+65.53% 24.73B
Weighted average by Cap. -1.23%+0.15%+75.55%+103.58%

Financials

2026 *2027 *
Net sales - 16.95M 14.73M 13.75M 12.62M 23.8M 1.62B 24.22M 162M 63.51M 806M 63.66M 62.25M 2.66B
Net income -15.78M -13.72M -12.81M -11.76M -22.17M -1.5B -22.55M -151M -59.14M -750M -59.29M -57.97M -2.47B -1.12M -969K -905K -831K -1.57M -106M -1.59M -10.67M -4.18M -53.01M -4.19M -4.1M -175M
Net Debt - -
Logo Evaxion A/S
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Employees
46
Date Price Change Volume
26-08-03 US$2.790 -1.06% 7,808
26-07-31 US$2.820 -0.35% 15,521
26-07-30 US$2.830 -0.35% 7,997
26-07-29 US$2.840 +1.43% 13,406
26-07-28 US$2.800 -3.11% 21,208
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.790USD
Average target price
11.25USD
Spread / Average Target
+303.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVAX Stock